Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues - Engineered Osteochondral Tissue

Inclusion Criteria: * Age: Subjects who are in the age range of 18-60 years * Location: Single symptomatic cartilage defect on medial or lateral femoral condyle * Size \& Containment: Contained single focal cartilage lesion of size \~1-4 cm square * Grading: Cartilage damage ICRS/Outerbridge grade III/IV reaching subchondral bone (As diagnosed by MRI) * Conservative treatments failed (for \> 4 months) Exclusion Criteria: Disease Factor--- * Previous cartilage repair surgery (OATS or ACI/MACI) in the index knee * Previous injectional treatments such as HA/PRP/stem cell in the index knee within 3 months before informed consent * Presence of a clinically relevant patellofemoral cartilage lesion in the index knee (patella/trochlea/both) * Inflammatory joint disease (specific or non-specific arthritis) * Metabolic diseases (gout or rheumatism) * Advanced Osteoarthritis (Radiologically apparent degenerative joint disease in the target knee as determined by Kellgren \& Lawrence Grade \>2) * Osteochondritis dissecans * Multiple or uncontained lesions as detected by MRI or arthroscopy * Uncorrected ligament deficiency * Uncorrected varus or valgus malalignment exceeding 5° * Ongoing Infection or skin diseases at target knee joint * Significant meniscal loss Patient Factor--- * Subjects who are not able or not willing to give voluntary, written informed consent to participate in this study * Skeletal immaturity * Female subjects who are pregnant or lactating * Body mass index \> …